1. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31.
2. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2003;10(3):160–84.
3. Munar-Qués M, Saraiva MJ, Viader-Farré C, Zabay-Becerril JM, Mulet-Ferrer J. Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis. 2005;12(1):54–61.
4. Raya-Cruz M, Buades-Reines J, Gallego-Lezáun C, Ripoll-Vera T, Usón-Martín M. Clinical and analytical variability in cases of familial amyloidotic polyneuropathy (PAF-TTR): comparison between healthy carriers and symptomatic patients. Med Balear. 2015;30(3):31–6.
5. Ueda M, Ando Y. Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener. 2014;3:19.